An inhibitor of methionine aminopeptidase type-2, PPI-2458, ameliorates the pathophysiological disease processes of rheumatoid arthritis

Autor: A. B. Rogers, Matthew T. Labenski, E. G. Doyle, E. J. Clark, D. D. Lazarus, R. M. Karp, W. F. Westlin, G. Hannig, S. G. Bernier, J. D. Wakefield, J. Lorusso, Charles D. Thompson, J. G. Hoyt
Rok vydání: 2008
Předmět:
Zdroj: Inflammation Research. 57:18-27
ISSN: 1420-908X
1023-3830
Popis: To elucidate the role of methionine aminopeptidase type-2 (MetAP-2) in the clinical pathology of rheumatoid arthritis, arthritis was induced in rats by administration of peptidoglycan-polysaccharide (PG-PS).The inhibitor of MetAP-2, PPI-2458, was administered orally at 5 mg/kg every other day during 3 distinct phases of the disease. In vitro studies were performed to clarify in vivo findings.Ankle swelling was completely alleviated by MetAP-2 inhibition. Inhibition of MetAP-2 in blood and tissues correlated with protection against PG-PS-induced arthritis. Histopathology of the tarsal joints improved following PPI-2458 administration, including a significant improvement of bone structure. In in vitro studies, osteoclast formation and activity were inhibited by PPI-2458, a mechanism not previously attributed to MetAP-2 inhibition.The important role that MetAP-2 has in the pathophysiological disease processes of PG-PS arthritis provides a strong rationale for evaluating PPI-2458 as a disease modifying antirheumatic treatment for rheumatoid arthritis.
Databáze: OpenAIRE